Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell LymphomaBusiness Wire • 04/01/25
Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDABusiness Wire • 03/03/25
Wall Street's Insights Into Key Metrics Ahead of Amneal (AMRX) Q4 EarningsZacks Investment Research • 02/25/25
Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades StockBenzinga • 02/24/25
Amneal Pharmaceuticals (AMRX) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 02/21/25
Wall Street Analysts Predict a 27.12% Upside in Amneal (AMRX): Here's What You Should KnowZacks Investment Research • 02/03/25
Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025Business Wire • 01/29/25
Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for RifaximinBusiness Wire • 01/23/25
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 AgonistBusiness Wire • 11/21/24
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hit a 52 Week High, Can the Run Continue?Zacks Investment Research • 11/12/24
Amneal (AMRX) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 11/08/24
Amneal Pharmaceuticals (AMRX) Surpasses Q3 Earnings and Revenue EstimatesZacks Investment Research • 11/08/24